<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27982267</article-id><article-id pub-id-type="pmc">5137384</article-id><article-id pub-id-type="doi">10.5935/abc.20160149</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group><subj-group><subject>Angioplasty with or without Stenting</subject></subj-group></article-categories><title-group><article-title>In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of
No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized
Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lago</surname><given-names>Igor Matos</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Novaes</surname><given-names>Gustavo Caires</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Badran</surname><given-names>Andr&#x000e9; Vannucchi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pav&#x000e3;o</surname><given-names>Rafael Brolio</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barbosa</surname><given-names>Ricardo</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>de Figueiredo</surname><given-names>Geraldo Luiz</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Moys&#x000e9;s de Oliveira</given-names><suffix>Filho</suffix></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haddad</surname><given-names>Jorge Luiz</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schmidt</surname><given-names>Andr&#x000e9;</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marin</surname><given-names>Jos&#x000e9; Ant&#x000f4;nio</given-names><suffix>Neto</suffix></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Divis&#x000e3;o de Cardiologia, Departamento de
Cl&#x000ed;nica M&#x000e9;dica, Hospital das Cl&#x000ed;nicas da Faculdade de Medicina
de Ribeir&#x000e3;o Preto - Universidade de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP -
Brazil</aff><aff id="aff2"><label>2</label>Hospital S&#x000e3;o Joaquim, Franca, SP - Brazil</aff><author-notes><corresp id="c1"><bold>Mailing Address: Jos&#x000e9; Ant&#x000f4;nio Marin
Neto</bold>, Rua Dr. Jo&#x000e3;o Gomes Rocha, 880 - Apto.201, Edif&#x000ed;cio
Victoria Hill. Postal Code 14.020-550, Jardim Iraj&#x000e1;, Ribeir&#x000e3;o
Preto, SP - Brazil . E-mail: <email>jamarin@cardiol.br</email>,
<email>marin_neto@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>11</month><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>11</month><year>2016</year></pub-date><volume>107</volume><issue>5</issue><fpage>403</fpage><lpage>410</lpage><history><date date-type="received"><day>19</day><month>1</month><year>2016</year></date><date date-type="rev-recd"><day>18</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>6</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Despite successful opening of culprit coronary artery, myocardial reperfusion
does not always follows primary percutaneous coronary intervention (PPCI).
Glycoprotein IIb/IIIa inhibitors are used in the treatment of no-reflow
(NR), but their role to prevent it is unproven.</p></sec><sec><title>Objective</title><p>To evaluate the effect of in-lab administration of tirofiban on the incidence
of NR in ST-elevation myocardial infarction (STEMI) treated with PPCI.</p></sec><sec><title>Methods</title><p>STEMI patients treated with PPCI were randomized (24 tirofiban and 34
placebo) in this double-blinded study to assess the impact of intravenous
tirofiban on the incidence of NR after PPCI according to angiographic and
electrocardiographic methods. End-points of the study were: TIMI-epicardial
flow grade; myocardial blush grade (MBG); resolution of ST-elevation &#x0003c;
70% (RST &#x0003c; 70%) at 90min and 24h after PPCI.</p></sec><sec><title>Results</title><p>Baseline anthropometric, clinical and angiographic characteristics were
balanced between the groups. The occurrence of TIMI flow &#x0003c; 3 was not
significantly different between the tirofiban (25%) and placebo (35.3%)
groups. MBG &#x02264; 2 did not occur in the tirofiban group, and was seen in
11.7% of patients in the placebo group (p=0.13). RST &#x0003c; 70% occurred in
41.6% x 55.8% (p=0.42) at 90min and in 29% x 55.9% (p=0.06) at 24h in
tirofiban and placebo groups, respectively. Severe NR (RST &#x02264; 30%) was
detected in 0% x 26.5% (p=0.01) at 90 min, and in 4.2% x 23.5% (p=0.06) at
24h in tirofiban and placebo groups, respectively.</p></sec><sec><title>Conclusion</title><p>This pilot study showed a trend toward reduction of NR associated with in-lab
upfront use of tirofiban in STEMI patients treated with PPCI and paves the
way for a full-scale study testing this hypothesis.</p></sec></abstract><kwd-group><kwd>Coronary Artery Disease</kwd><kwd>Myocardial Infarction</kwd><kwd>Percutaneous Coronary Intervention</kwd><kwd>Platelet Glycoprotein GPIIb-IIIa Complex</kwd><kwd>Angioplasty</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>After sudden death, acute ST-segment elevation myocardial infarction (STEMI) is the
second most severe clinical presentation of coronary artery disease (CAD) in the US
and Europe.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref></sup> For more than one decade, primary percutaneous
coronary intervention (PPCI) has been considered the most appropriate treatment to
restore myocardial blood flow and, consequently, favorably impact survival<sup><xref rid="r3" ref-type="bibr">3</xref></sup> . Despite epicardial coronary flow
being established in the culprit artery, a substantial proportion of patients do not
achieve adequate myocardial reperfusion, known as the no-reflow (NR)
phenomenon.<sup><xref rid="r4" ref-type="bibr">4</xref></sup> The NR
phenomenon has a negative influence on PPCI<sup><xref rid="r5" ref-type="bibr">5</xref></sup> due to its association with a greater myocardial necrosis
area and more intense irreversible left ventricular systolic dysfunction, which are
independent predictors of mortality.<sup><xref rid="r6" ref-type="bibr">6</xref></sup> Various therapeutic measures including pharmacologic approaches
and mechanical devices have been used to manage the two principal pathophysiological
mechanisms leading to NR, i.e. microvascular spasm, and clot and distal embolism of
plaque debris.<sup><xref rid="r7" ref-type="bibr">7</xref></sup> However, the role
of each of these therapeutic resources, including the use of IIb/IIIa glycoprotein
inhibitors (GPI), is still inconclusive, especially for the prevention of NR. Hence,
with the current therapeutic management of patients with STEMI undergoing PPCI, that
includes dual antiplatelet therapy and antithrombin agents, an investigation about
the systematic upfront in-lab use of a GPI to lower the occurrence of NR is
appropriate, especially when bare-metal stents are implanted, as in most developing
countries. This was the scope of this pilot randomized study, which compared the
incidence of NR in STEMI patients treated with PPCI and tirofiban or placebo.</p></sec><sec sec-type="methods"><title>Methods</title><p>From August 2011 through January 2014, 64 patients with STEMI referred for PPCI by
the emergency health care system were enrolled at two tertiary hospitals, located in
Ribeir&#x000e3;o Preto and in Franca, state of S&#x000e3;o Paulo, Brazil. Patients or
their responsible relatives signed informed consent forms, approved by the Ethics
Committee of Ribeir&#x000e3;o Preto General Hospital, University of S&#x000e3;o Paulo
Medical School , responsible for the two hospital centers participating in the
investigation (Process 2495/2010).</p><p>Using a centralized, unrestricted (simple) randomization system, 58 patients were
randomized to receive intravenous infusions of tirofiban (n=24) or placebo (n=34 )
in a double blind manner. The inclusion criteria consisted of: age &#x02265;18 years,
typical thoracic pain &#x02265; 20 minutes and &#x0003c; 12 hours duration, ST segment
elevation &#x02265; 1mm in two contiguous leads or presumed new left bundle-branch
block. Six of the referred patients were excluded, based on the following criteria:
cardiogenic shock, prior myocardial infarction in the same ventricular wall as the
current coronary event, known bleeding diathesis, coma, severe hepatic dysfunction
or severe renal insufficiency (Creatinine &#x0003e; 3.0 mg/dL), contraindications for
acetylsalicylic acid (ASA) , clopidogrel or heparin, life expectancy &#x0003c;1 year,
previous major surgery &#x0003c; 3 months, stroke &#x0003c; 30 days, previously known
intracranial aneurism or arteriovenous malformation, severe trauma &#x0003c; 6 weeks, use
of oral anticoagulant; inability to give written informed consent.</p><p>Immediately after randomization of patients , the infusion solutions were prepared by
a registered nurse, who was the only person aware of which treatment was
administered to each person . Placebo or tirofiban (25mcg/Kg) were administered
intravenously in bolus of 10 ml over 3min as soon as the patients entered in the
catheterization laboratory. In both arms of the trial, equivalent volumes were then
infused for 12 hour s, so that tirofiban was administered at the dose of
0.15mcg/Kg/min. Unfractionated heparin boluses were administered in a dose of 70U/Kg
for the patients in the tirofiban group and of 100U/Kg in the placebo group, by the
same nurse who prepared the solutions . All other clinical and laboratory procedures
related to the PPCI after the patient left the cath lab, regarding medications, use
of thrombus aspiration catheters, and laboratory tests were left at the discretion
of the interventional physician. The therapeutic procedure was limited to the
infarct related culprit artery. NR was diagnosed through angiographic epicardial
flow and myocardial blush grade (MBG) criteria, by the attending physician during
PPCI, to assess the requirement for other medications, including intracoronary
nitroglycerin, adenosine or verapamil. After the end of PPCI, a blinded reevaluation
of the angiographic grading of epicardial flow and myocardial blush was performed by
a consensus of two experienced interventionists. They also blindly evaluated the
occurrence of NR by analysis of ST segment elevation resolution on the
electrocardiogram at 90 minutes and 24 hours post-PPCI. In case of discordance, a
third opinion was called to achieve a consensus. Time intervals assessed in the
study included time from onset of chest pain to arrival at the emergency room , time
from initial pain to arrival at the cath lab, and duration of the diagnostic and
therapeutic procedures. Clinical complications and duration of hospitalization were
also recorded.</p><p>Sample size was calculated assuming a NR incidence of 70% in the placebo group based
on a ST segment resolution &#x0003e; 70% (no resolution) at 90 minutes after the PPCI .
The study hypothesis was that, using this criterion, NR incidence would be reduced
by 50% in the tirofiban group, <italic>i.e.</italic>, an expected incidence of about
35%, with 80% power and two-tailed &#x003b1; = 0.05. The calculation resulted in a
total of 56 patients, with 28 in each group.<sup><xref rid="r8" ref-type="bibr">8</xref></sup> Statistical analysis was performed using the programs
STATA.<sup><xref rid="r9" ref-type="bibr">9</xref></sup> The normal
distribution of each variable analyzed was verified by Shapiro-Wilk test; the
quantitative variables with normal distribution were described as mean (M) and
standard deviation (&#x000b1; SD), and the categorical variables were described as
absolute values and as frequency (n) and percentage (%). Continuous variables with
and without normal distribution were analyzed by parametrical Student's t-test and
Mann-Whitney test, respectively. Chi-square and Fisher exact tests were used for
categorical variables. Multivariable analysis by logistic regression was made to
identify independent predictors of post-PPCI ST resolution with the following
dichotomous variables: tirofiban/placebo use; PPCI initial time, time from onset of
chest pain; post-PPCI Thrombolysis In Myocardial Infarction (TIMI) flow grade ;
coronary nitrate and adenosine administration; use of catheters for the mechanic
aspiration of thrombus; stent post-dilation during PPCI. The significance level of
0.05 was set for all comparisons.</p></sec><sec sec-type="results"><title>Results</title><p>Of the 64 patients enrolled, 6 had to be excluded after randomization - 3 for
protocol violations, 1 due to absence of culprit lesion and 1 because of ensuing
cardiogenic shock. Of the remaining 58 patients, 34 patients were allocated to the
placebo group and 24 patients to the tirofiban group. The main baseline clinical
characteristics including previous medications were similar between groups (<xref ref-type="table" rid="t1">Table 1</xref>). With regard to the 3 patients with
previous coronary events all were in the tirofiban group and had previous P PCI
(p=0.06). Cocaine use was identified in 1 patient of the placebo group (p=1.00). The
majority of patients in both groups reached the cath lab within 6 hours of the onset
of symptoms (83.3% in the tirofiban group and 77.6% in the placebo group), and most
of them were classified as Killip-Kimball class I or II.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Tirofiban (%) <sup><xref ref-type="table-fn" rid="TFN5">&#x000b6;</xref></sup></th><th align="center" rowspan="1" colspan="1">Placebo (%) <sup><xref ref-type="table-fn" rid="TFN6">&#x003a9;</xref></sup></th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patients</td><td align="center" rowspan="1" colspan="1">24 (41.4%)</td><td align="center" rowspan="1" colspan="1">34 (58.6%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">59.5 (&#x000b1;10.5)</td><td align="center" rowspan="1" colspan="1">58.3 (&#x000b1;11.9)</td><td align="center" rowspan="1" colspan="1">(=0.70) <sup><xref ref-type="table-fn" rid="TFN3">&#x00162;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">19 (79.2%)</td><td align="center" rowspan="1" colspan="1">30 (88.2%)</td><td align="center" rowspan="1" colspan="1">(=0.46) <bold><sup><xref ref-type="table-fn" rid="TFN2">&#x00192;</xref></sup></bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="center" rowspan="1" colspan="1">22 (91.6%)</td><td align="center" rowspan="1" colspan="1">27 (79.4%)</td><td align="center" rowspan="1" colspan="1">(=0.28) <sup><xref ref-type="table-fn" rid="TFN2">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">BMI&#x000a0;&#x000a0; &#x02265; 30</td><td align="center" rowspan="1" colspan="1">5 (20.8 %)</td><td align="center" rowspan="1" colspan="1">7 (20.6%)</td><td align="center" rowspan="1" colspan="1">(=1.00) <sup><xref ref-type="table-fn" rid="TFN2">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">16 (66.6%)</td><td align="center" rowspan="1" colspan="1">23 (67.6%)</td><td align="center" rowspan="1" colspan="1">(=0.84) <sup><xref ref-type="table-fn" rid="TFN4">&#x003c7;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Smokers</td><td align="center" rowspan="1" colspan="1">13 (54.2%)</td><td align="center" rowspan="1" colspan="1">16 (47.1%)</td><td align="center" rowspan="1" colspan="1">(=0.79) <sup><xref ref-type="table-fn" rid="TFN4">&#x003c7;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" rowspan="1" colspan="1">10 (41.6%)</td><td align="center" rowspan="1" colspan="1">11 (32.4%)</td><td align="center" rowspan="1" colspan="1">(=0.58) <sup><xref ref-type="table-fn" rid="TFN4">&#x003c7;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CAD Family History</td><td align="center" rowspan="1" colspan="1">5 (20.8%)</td><td align="center" rowspan="1" colspan="1">12 (35.3%)</td><td align="center" rowspan="1" colspan="1">(=0.26) <sup><xref ref-type="table-fn" rid="TFN2">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">3 (12.5%)</td><td align="center" rowspan="1" colspan="1">7 (20.6%)</td><td align="center" rowspan="1" colspan="1">(=0.49) <sup><xref ref-type="table-fn" rid="TFN2">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">ACEI/ARB</td><td align="center" rowspan="1" colspan="1">10 (41.6%)</td><td align="center" rowspan="1" colspan="1">15 (44.1%)</td><td align="center" rowspan="1" colspan="1">(=1.00) <sup><xref ref-type="table-fn" rid="TFN2">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Oral antidiabetic</td><td align="center" rowspan="1" colspan="1">3 (12.5%)</td><td align="center" rowspan="1" colspan="1">8 (23.5%)</td><td align="center" rowspan="1" colspan="1">(=0.33) <sup><xref ref-type="table-fn" rid="TFN2">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Statin</td><td align="center" rowspan="1" colspan="1">6 (25%)</td><td align="center" rowspan="1" colspan="1">3 (8.8%)</td><td align="center" rowspan="1" colspan="1">(=0.14) <sup><xref ref-type="table-fn" rid="TFN2">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">ASA</td><td align="center" rowspan="1" colspan="1">2 (8.3%)</td><td align="center" rowspan="1" colspan="1">4 (11.7%)</td><td align="center" rowspan="1" colspan="1">(=1.00) <sup><xref ref-type="table-fn" rid="TFN2">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Diuretics</td><td align="center" rowspan="1" colspan="1">1 (4.2%)</td><td align="center" rowspan="1" colspan="1">5 (14.7%)</td><td align="center" rowspan="1" colspan="1">(=0.38) <sup><xref ref-type="table-fn" rid="TFN2">&#x00192;</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>BMI: body mass index; CAD: coronary artery disease; ACEI: angiotensin
converting enzyme inhibitor; ARB: angiotensin receptor blocker; ASA:
acetylsalicylic acid; p: p-value;</p></fn><fn id="TFN2"><label>&#x00192;</label><p>p-value calculated by Fisher Exact Test;</p></fn><fn id="TFN3"><label>&#x00162;</label><p>p-value calculated by &#x0201c;t&#x0201d; Student Test (95% IC 4.86-7.26);</p></fn><fn id="TFN4"><label>&#x003a7;</label><p>p-value calculated by Chi-square Test;</p></fn><fn id="TFN5"><label>&#x000b6;</label><p>tirofiban percentage group;</p></fn><fn id="TFN6"><label>&#x003a9;</label><p>placebo percentage group</p></fn></table-wrap-foot></table-wrap><p>
<xref ref-type="table" rid="t2">Table 2</xref> shows technical aspects of the
diagnostic cardiac catheterization procedure that was performed using right radial
arterial approach in 23 (95.8%) of tirofiban patients and in 31 (91.2%) placebo
patients (p=1.00). In 57 patients (98.3%) a 6F sheath was inserted. Per protocol,
all patients in both groups were treated with ASA 300mg, and clopidogrel 300mg
before the cardiac catheterization was initiated. Left contrast ventriculography was
done at the end of the procedure in 44 (75.6%) patients, 19 (79.2%) from the
tirofiban group and 25 (73.5%) from the placebo group. Moderate impairment of global
systolic left ventricular (LV) function occurred 15 (60%) patients of the placebo
group, opposed to 5 (26.3%) of the tirofiban group (p=0.03). No other angiographic
differences were seen when comparing both groups (<xref ref-type="table" rid="t2">Table 2</xref>), including the duration of the diagnostic procedure with an
average of 16.7 (&#x000b1;11.2) minutes in the tirofiban group and of 13.7
(&#x000b1;9.8) minutes in the placebo group (p=0.11).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Characteristics of diagnostic catheterization</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">LV/EF</th><th align="center" rowspan="1" colspan="1">(19 Tirofiban) <sup><xref ref-type="table-fn" rid="TFN10">&#x000b6;</xref></sup> (%) <xref ref-type="table-fn" rid="TFN9">&#x003c5;</xref></th><th align="center" rowspan="1" colspan="1">(25 Placebo)<sup><xref ref-type="table-fn" rid="TFN11">&#x003a9;</xref></sup> (%) <xref ref-type="table-fn" rid="TFN9">&#x003c5;</xref></th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x0003c; 30%</td><td align="center" rowspan="1" colspan="1">4 (21.1%)</td><td align="center" rowspan="1" colspan="1">2 (8%)</td><td align="center" rowspan="1" colspan="1">(=0.34) <sup><xref ref-type="table-fn" rid="TFN8">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">31-40%</td><td align="center" rowspan="1" colspan="1">5 (26.3%)</td><td align="center" rowspan="1" colspan="1">15 (60%)</td><td align="center" rowspan="1" colspan="1">(=0.03) <sup><xref ref-type="table-fn" rid="TFN8">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">41-50%</td><td align="center" rowspan="1" colspan="1">6 (31.5%)</td><td align="center" rowspan="1" colspan="1">6 (24%)</td><td align="center" rowspan="1" colspan="1">(=0.73) <sup><xref ref-type="table-fn" rid="TFN8">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">No Ventriculography</td><td align="center" rowspan="1" colspan="1">5 (26.3%)</td><td align="center" rowspan="1" colspan="1">9 (36%)</td><td align="center" rowspan="1" colspan="1">(=0.53) <sup><xref ref-type="table-fn" rid="TFN8">&#x00192;</xref></sup></td></tr><tr style="border-bottom-width:thin;border-bottom-style:solid;border-top-width:thin;border-top-style:solid"><td align="left" rowspan="1" colspan="1">CAD pattern and grade of luminal obstruction</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">UNIARTERIAL</td><td align="center" rowspan="1" colspan="1">14 (58.3%)</td><td align="center" rowspan="1" colspan="1">21 (61.7%)</td><td align="center" rowspan="1" colspan="1">(=1.00) <sup><xref ref-type="table-fn" rid="TFN8">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">BIARTERIAL</td><td align="center" rowspan="1" colspan="1">7 (29.2%)</td><td align="center" rowspan="1" colspan="1">8 (23.5%)</td><td align="center" rowspan="1" colspan="1">(=0.76) <sup><xref ref-type="table-fn" rid="TFN8">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">TRIARTERIAL</td><td align="center" rowspan="1" colspan="1">3 (12.5%)</td><td align="center" rowspan="1" colspan="1">5 (14.7%)</td><td align="center" rowspan="1" colspan="1">(=1.00) <sup><xref ref-type="table-fn" rid="TFN8">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">100 %</td><td align="center" rowspan="1" colspan="1">19 (79.2%)</td><td align="center" rowspan="1" colspan="1">29 (85.3%)</td><td align="center" rowspan="1" colspan="1">(=0.73) <sup><xref ref-type="table-fn" rid="TFN8">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">71 - 99 %</td><td align="center" rowspan="1" colspan="1">5 (20.8%)</td><td align="center" rowspan="1" colspan="1">4 (11.7%)</td><td align="center" rowspan="1" colspan="1">(=0.46) <sup><xref ref-type="table-fn" rid="TFN8">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">51 - 70 %</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">1 (2.9%)</td><td align="center" rowspan="1" colspan="1">(=1.00) <sup><xref ref-type="table-fn" rid="TFN8">&#x00192;</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><p>LV: left ventriculography; EF: ejection fraction; CAD: coronary artery
disease; p: p-value;</p></fn><fn id="TFN8"><label>&#x00192;</label><p>p value calculated by Fisher Exact Test;</p></fn><fn id="TFN9"><label>&#x003c5;</label><p>only for patients that were submitted to LV;</p></fn><fn id="TFN10"><label>&#x000b6;</label><p>tirofiban group percentage;</p></fn><fn id="TFN11"><label>&#x003a9;</label><p>p lacebo group percentage.</p></fn></table-wrap-foot></table-wrap><p>The main characteristics of the therapeutic procedure are shown on <xref ref-type="table" rid="t3">table 3</xref>. All patients were instrumented with
the same arterial approach and sheath diameters used for the diagnostic procedure.
Bare metal stents were exclusively used in all procedures, with a similar rate in
both groups, 1.37 stent/patient in the tirofiban group and 1.29 stent/patient in the
placebo group (p=0.75). PPCI with balloon was performed in only one patient
allocated to the tirofiban group. A trend for more post-stent dilation was observed
in the placebo group (p=0.06). The time from patients' arrival at the ca th lab to
the start of intravenous administration of tirofiban or placebo was similar in both
groups, 6.26 (&#x000b1;3.1) minutes in the tirofiban group and 8.52 (&#x000b1;6.4)
minutes in the placebo group. Clinical complications occurred in similar proportions
of patients in both groups: systolic arterial pressure &#x0003c; 90mmHg in 5 (20.8%)
tirofiban patients and in 5 (14.7%) placebo patients (p=0.73); heart rate &#x0003e;
100bpm in 4 (16.6%) tirofiban patients and in 2 (5.8%) placebo patients (p=0.22);
bradyarrhythmia in 4 (16.6%) tirofiban patients and in 1 (2.9%) placebo patient
(p=0.15). One (1.7%) tirofiban patient had a successfully resuscitated cardiac
arrest (p=0.41); severe hypotension or shock was present in 3 (12.5%) tirofiban
patients and in 2 (5.8%) placebo patients (p=0.64); small hematoma at the vascular
access site , according to TIMI classification, was present in 4 (16.6%) tirofiban
patients and in 3 (8.8%) placebo patients (p=0.43); hemorrhagic stroke occurred in 1
patient of the placebo group 3 days after PPCI (p=1.00). The duration of the
therapeutic procedure was similar in both groups, 31.8 (&#x000b1; 20.2) minutes in
tirofiban group and of 35.4 (&#x000b1; 22.7) minutes in placebo group (p=0.47).
Thrombus manual aspiration during the therapeutic procedure and utilization of other
medications were also similar in both groups (<xref ref-type="table" rid="t3">Table
3</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Characteristics of therapheutic procedure</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">PPCI</th><th align="center" rowspan="1" colspan="1">Tirofiban(%) <sup><xref ref-type="table-fn" rid="TFN16">&#x000b6;</xref></sup></th><th align="center" rowspan="1" colspan="1">Placebo (%) <sup><xref ref-type="table-fn" rid="TFN17">&#x003a9;</xref></sup></th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Direct Stent</td><td align="center" rowspan="1" colspan="1">7 (29.2%)</td><td align="center" rowspan="1" colspan="1">14 (41.2%)</td><td align="center" rowspan="1" colspan="1">(=0.41) <sup><xref ref-type="table-fn" rid="TFN14">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Predilation</td><td align="center" rowspan="1" colspan="1">17 (70.8%)</td><td align="center" rowspan="1" colspan="1">20 (58.8%)</td><td align="center" rowspan="1" colspan="1">(=0.41) <sup><xref ref-type="table-fn" rid="TFN14">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Postdilation</td><td align="center" rowspan="1" colspan="1">1 (4.2%)</td><td align="center" rowspan="1" colspan="1">8 (23.5%)</td><td align="center" rowspan="1" colspan="1">(=0.06) <sup><xref ref-type="table-fn" rid="TFN14">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Maximal Stent Pressure</td><td align="center" rowspan="1" colspan="1">13.4&#x000b1;2.1 <bold><xref ref-type="table-fn" rid="TFN15">&#x003c5;</xref></bold></td><td align="center" rowspan="1" colspan="1">13.8&#x000b1;2.4 <bold><xref ref-type="table-fn" rid="TFN15">&#x003c5;</xref></bold></td><td align="center" rowspan="1" colspan="1">(=0.10) <sup><xref ref-type="table-fn" rid="TFN13">&#x003a3;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02264; 12</td><td align="center" rowspan="1" colspan="1">16 (20.%) <bold><xref ref-type="table-fn" rid="TFN15">&#x003c5;</xref></bold></td><td align="center" rowspan="1" colspan="1">10 (12.9%)<bold><xref ref-type="table-fn" rid="TFN15">&#x003c5;</xref></bold></td><td align="center" rowspan="1" colspan="1">(=0.03) <sup><xref ref-type="table-fn" rid="TFN14">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">13 A 15</td><td align="center" rowspan="1" colspan="1">11 (37.9%) <bold><xref ref-type="table-fn" rid="TFN15">&#x003c5;</xref></bold></td><td align="center" rowspan="1" colspan="1">22 (52.4%)<bold><xref ref-type="table-fn" rid="TFN15">&#x003c5;</xref></bold></td><td align="center" rowspan="1" colspan="1">(=0.18) <sup><xref ref-type="table-fn" rid="TFN14">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;16</td><td align="center" rowspan="1" colspan="1">6 (7.8%) <bold><xref ref-type="table-fn" rid="TFN15">&#x003c5;</xref></bold></td><td align="center" rowspan="1" colspan="1">12 (15.6%)<bold><xref ref-type="table-fn" rid="TFN15">&#x003c5;</xref></bold></td><td align="center" rowspan="1" colspan="1">(=0.42) <sup><xref ref-type="table-fn" rid="TFN14">&#x00192;</xref></sup></td></tr><tr style="border-bottom-width:thin;border-bottom-style:solid;border-top-width:thin;border-top-style:solid"><td align="left" rowspan="1" colspan="1"><bold>Nr Therapy</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Nitroglycerin</td><td align="center" rowspan="1" colspan="1">7 (29.2%)</td><td align="center" rowspan="1" colspan="1">13 (38.2%)</td><td align="center" rowspan="1" colspan="1">(=0.58) <sup><xref ref-type="table-fn" rid="TFN14">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Adenosine</td><td align="center" rowspan="1" colspan="1">3 (12.5%)</td><td align="center" rowspan="1" colspan="1">10 (29.4%)</td><td align="center" rowspan="1" colspan="1">(=0.21) <sup><xref ref-type="table-fn" rid="TFN14">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Manual Aspiration of Thrombus</bold></td><td align="center" rowspan="1" colspan="1">4 (16.6%)</td><td align="center" rowspan="1" colspan="1">7 (20.6%)</td><td align="center" rowspan="1" colspan="1">(=1.00) <sup><xref ref-type="table-fn" rid="TFN14">&#x00192;</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN12"><p>PPCI: primary percutaneous coronary intervention; NR: no reflow; p: p
value;</p></fn><fn id="TFN13"><label>&#x003a3;</label><p>p value calculated by Mann-Whitney Test;</p></fn><fn id="TFN14"><label>&#x00192;</label><p>p-value calculated by Fisher Exact Test;</p></fn><fn id="TFN15"><label>&#x003c5;</label><p>numbers of sent values;</p></fn><fn id="TFN16"><label>&#x000b6;</label><p>tirofiban group percentage;</p></fn><fn id="TFN17"><label>&#x003a9;</label><p>placebo group percentage.</p></fn></table-wrap-foot></table-wrap><p>According to the angiographic criteria of epicardial TIMI flow grade &#x0003c; 3, the
incidence of NR at the end of PPCI was not different between groups: 6 (25%)
tirofiban patients and in 12 (35.3%) placebo patients (<xref ref-type="table" rid="t4">Table 4</xref>). By the angiographic criteria of MBG &#x0003c; 2 at the end
of PPCI, NR did not occur in any patient of the tirofiban group and was detected in
4 patients of the placebo group (11.7%), but this difference was not statistically
significant. By the ECG criteria (STR &#x0003c; 70%), NR occurred in 10 patients (41.6%)
in the tirofiban group and 19 patients (55.8%) in the placebo group at 90 minutes
after the PPCI (p=0.42). Also, 7 (29%) of tirofiban patients and 19 (55.8%) placebo
patients met the criteria for NR at 24 hours (p=0.06). When the criteria of severe
NR (STR &#x0003c; 30%) was used, no tirofiban patient and 9 (26.5%) placebo patients met
it at 90 minutes (p=0.01) and 1 (4.2%) tirofiban patient and 8 (23.5%) placebo
patients had severe NR at 24 hours (p=0.06).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Assessment of reperfusion achieved with ppci</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">TIMI/MBG GRADES</th><th align="center" rowspan="1" colspan="1">Tirofiban (%) <sup><xref ref-type="table-fn" rid="TFN21">&#x000b6;</xref></sup></th><th align="center" rowspan="1" colspan="1">Placebo (%) <sup><xref ref-type="table-fn" rid="TFN22">&#x003a9;</xref></sup></th><th align="center" rowspan="1" colspan="1">p </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>TIMI PRE-PPCI</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0-2 x 3</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">22 (91.6%)</td><td align="center" rowspan="1" colspan="1">29 (85.3%)</td><td align="center" rowspan="1" colspan="1">(=1.00) <sup><xref ref-type="table-fn" rid="TFN19">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">1 (2.9%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2 (8.3%)</td><td align="center" rowspan="1" colspan="1">2(5.8%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">2 (5.8%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TIMI POST-PPCI</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0-2 x 3</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">(=0.40) <sup><xref ref-type="table-fn" rid="TFN19">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">1 (2.9%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">6 (25%)</td><td align="center" rowspan="1" colspan="1">12 (35.3%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">18 (75%)</td><td align="center" rowspan="1" colspan="1">21 (61.7%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>MBG PRE-PPCI</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0-1 x 2-3</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">22 (91.6%)</td><td align="center" rowspan="1" colspan="1">29 (85.3%)</td><td align="center" rowspan="1" colspan="1">(=1.00) <sup><xref ref-type="table-fn" rid="TFN19">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">2 (5.8%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2 (8.3%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">3 (8.8%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>MBG POST-PPCI</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0&#x02013;1 x 2&#x02013;3</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">(=0.13) <sup><xref ref-type="table-fn" rid="TFN19">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">4 (11.7%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">11 (45.8%)</td><td align="center" rowspan="1" colspan="1">10 (29.4%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">13 (54.2%)</td><td align="center" rowspan="1" colspan="1">20 (58.8%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">ECG/STR</td><td align="center" rowspan="1" colspan="1">90 min</td><td align="center" rowspan="1" colspan="1">90 min</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">No STR (&#x0003c;30%)</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">9(26.5%)</td><td align="center" rowspan="1" colspan="1">(=0.01) <sup><xref ref-type="table-fn" rid="TFN19">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">STR (71-100%)</td><td align="center" rowspan="1" colspan="1">14 (58.3%)</td><td align="center" rowspan="1" colspan="1">15 (44.1%)</td><td align="center" rowspan="1" colspan="1">(=0.42) <sup><xref ref-type="table-fn" rid="TFN19">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">ECG/STR</td><td align="center" rowspan="1" colspan="1">24h</td><td align="center" rowspan="1" colspan="1">24h</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">NO STR (&#x0003c;30%)</td><td align="center" rowspan="1" colspan="1">1(4.2%)</td><td align="center" rowspan="1" colspan="1">8 (23.5%)</td><td align="center" rowspan="1" colspan="1">(=0.06) <sup><xref ref-type="table-fn" rid="TFN19">&#x00192;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">STR (71-100%)</td><td align="center" rowspan="1" colspan="1">17 (71%)</td><td align="center" rowspan="1" colspan="1">15 (44.1%)</td><td align="center" rowspan="1" colspan="1">(=0.06) <sup><xref ref-type="table-fn" rid="TFN19">&#x00192;</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN18"><p>TIMI: thrombolysis in myocardial infarction, according to the TIMI Study
Group (1985); MBG: myocardial blush grade, according to the Zwolle
Myocardial Infarction Study Group (VAN&#x02019;T HOF AW ,1998); PPCI: primary
percutaneous coronary intervention; ECG: electrocardiogram; STR: ST
elevation resolution; No STR: number of ST Elevation resolution</p></fn><fn id="TFN19"><label>&#x00192;</label><p>comparison of TIMI 0 and 1 versus, TIMI 2 and 3, MBG 0 and 1 versus MBG 2
and 3, and patients with and without STR at 90min and at 24hours by
Fisher Exact Test;</p></fn><fn id="TFN20"><p>&#x00162;: p-value calculated by Student t-test (95%IC,0.32-31.28);</p></fn><fn id="TFN21"><label>&#x000b6;</label><p>tirofiban percentage;</p></fn><fn id="TFN22"><label>&#x003a9;</label><p>placebo percentage.</p></fn></table-wrap-foot></table-wrap><p>No variable, including treatment with tirofiban or stent post-dilation during PPCI,
had predictable value for the occurrence of NR.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Despite the small sample population of the study, randomization assured homogeneity
between the two experimental groups for all the baseline characteristics such as
age, gender, obesity or overweight, coronary artery disease (CAD) risk factors,
previous use of anti-ischemic and anti-atherosclerotic medications. Also, time
elapsed between symptom onset and presentation to the cath lab, degree of LV
dysfunction and other characteristics that may influence the PPCI results (e.g. CAD
severity and extension and duration of procedures) were comparable between the
groups . Only depression of left ventricular ejection fraction was more marked in
the group treated with placebo, but this may reflect a worse baseline condition or a
result of a less successful PPCI.</p><p>As expected, the pre-PPCI epicardial and myocardial flow grades, expressed as TIMI-0
and MBG-0, were markedly predominant in both groups. In a small number of cases we
observed that spontaneous recanalization of the culprit artery had already begun
when the diagnostic angiography was performed.</p><p>Taking into consideration the angiographic criteria, NR was diagnosed in 32.8% of
patients, 25% of the tirofiban group and 38.3% of the placebo group (TIMI flow grade
&#x0003c; 3). This is a higher incidence of NR than has been predicted in the
literature.<sup><xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref></sup> In contrast, by the angiographic
criteria of myocardial reperfusion (MBG &#x0003c; 2), NR was detected in only 7.8% of
patients (all from the placebo group), an incidence similar to that referred in
previous investigations.<sup><xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref></sup> Although these differences between
the groups did not attain statistical significance, they show a tendency for a
better result of PPCI in the group treated with tirofiban, which contrasts with
previous findings.<sup><xref rid="r12" ref-type="bibr">12</xref></sup> Also, these
results confirm that angiographic analyses can detect only part of the occurrence of
NR. When the electrocardiographic criteria for NR (STR &#x0003c; 70%) was used, the first
analysis at 90 minutes led to the diagnosis of NR in 29 (50%) patients, 10 (41.6%)
in tirofiban group and 19 (55.8%) in placebo group; and the second analysis at 24
hours diagnosed NR in 26 patients (45%), 7 (29.2%) in tirofiban group and 19 (56%)
in placebo group. The differences between the groups were not statistically
significant, but there was a trend toward a benefit for a reduction in NR incidence
in the tirofiban group (p=0.06). When the severity of NR was assessed taking into
account a STR &#x0003c; 30%, severe NR was not detected in the tirofiban group at 90 min,
but it occurred in 9 (26.5%) patients of the placebo group at 90 minutes (p=0.01).
Also, at 24hours, severe NR was present in 1 (4.2%) tirofiban patient and in 8
(23.5%) placebo patients (p=0.06). These findings also support the notion of a
possible beneficial reduction of NR when tirofiban is administered early during the
PPCI for STEMI patients within the 12 hours after the onset of symptoms.</p><p>In addition, the differences in NR incidence between the groups were not related to
technical aspects of the PPCI procedure, such as characteristics of devices
(balloons, stents and others), or strategy and duration of therapy,<sup><xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref></sup> that may affect the occurrence of NR due to distal
embolization, since these parameters were not different between the groups. Also,
adjunctive therapy (nitrates, adenosine) was used in similar proportions in the two
groups. The use of manual thrombus aspiration device was more frequent in the
placebo group, but since it was not a protocol-mandated procedure, this may only
indicate that this was performed at the discretion of the operator (who was blinded
to the infusion solution).</p><p>Our sample calculation was mainly based on a previous clinical trial and a
meta-analysis, reporting that only 35% of the STEMI patients treated with PPCI would
achieve an optimal epicardial and myocardial perfusion, i.e., TIMI grade 3, MBG
grade 2 or 3 and STR &#x0003e; 70%, when the angiographic and electrocardiographic
criteria are taken into consideration altogether . Therefore, NR would be present in
65% of the patients.<sup><xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref></sup> Our findings support the need of a more integrated and
complementary use of all diagnostic criteria for NR. In fact, the differences of STR
between the analyses at 90min and 24h show that NR exhibits a dynamic time behavior
after PPCI, with a possible worsening of the condition at a later stage, as observed
with one patient in the tirofiban group.</p><p>The lower overall incidence of NR in our sample population in comparison with those
studies on which our hypothesis was based may be due to the fact that oral dual
antiplatelet therapy was not yet in widespread clinical practice in those studies.
In fact, our results are consistent with the findings of other studies that showed
that oral double antiplatelet therapy as a routine pre-PPCI management was superior
to only ASA to prevent hard clinical endpoints in STEMI patients.<sup><xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref></sup>
</p><p>The results of the current study are also in line with those of a North American
registry on more than 300,000 patients with STEMI treated with PPCI, reporting a NR
frequency of only 2.3% according to the angiographic TIMI grade criteria. Of note,
GPI was used in more than 70% of these patients.<sup><xref rid="r18" ref-type="bibr">18</xref></sup> However , studies with abciximab that showed a benefit in
mortality and reinfarction compared to placebo were performed when dual oral
antiplatelet therapy had not yet been adopted in routine,<sup><xref rid="r19" ref-type="bibr">19</xref>,<xref rid="r20" ref-type="bibr">20</xref></sup> and more
recent studies with low molecular weight GPI reported similar results.<sup><xref rid="r12" ref-type="bibr">12</xref></sup>
</p><p>The variability of the incidence and severity of NR reported in several studies may
also be due to the use of only one of the two existing angiographic criteria. Also,
there are disagreements between angiographic and electrocardiographic criteria, as
we found in the present study.<sup><xref rid="r11" ref-type="bibr">11</xref></sup>
For the assessment of myocardial reperfusion after PPCI, inadequate STR should be
considered a more reliable criterion for NR than the angiographic one , because it
carries inherent prognostic information.<sup><xref rid="r21" ref-type="bibr">21</xref></sup> Although in most of studies assessing NR with the STR
criteria, only one analysis was performed after 1hour of treatment,<sup><xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref></sup> we also analyzed STR at 24hours, considering that NR is a
dynamic phenomenon in a sizeable proportion of patients. It is important to
emphasize that these ECG analyses can be performed almost without additional cost,
in contrast with the use of magnetic resonance, myocardial scintigraphy and doppler
echocardiography , to assess myocardial reperfusion in the infarct area.</p><p>In conclusion, the results of this pilot study suggest that the in-lab upfront use of
tirofiban in STEMI patients treated with PPCI may reduce the occurrence and severity
of NR, and provide support for a definitive trial to assess the role of GPIs to
prevent NR and reduce hard clinical endpoints in this context. The role of IIb/IIIa
inhibitors also remains to be determined for patients being treated with novel
antagonists of the P2Y12 receptor, such as prasugrel and ticagrelor, possibly in
boluses administration to reduce the bleeding risk and to reduce the thrombotic risk
during the initial gap in the effectiveness of the antiplatelet regimen. The
recently approved inhibitor cangrelor may also constitute a valuable option in the
context, due to the inherent fast onset and clearance of its antiplatelet
effect.<sup><xref rid="r24" ref-type="bibr">24</xref></sup>
</p><sec><title>Limitations</title><p>We acknowledge that the study has several limitations, such as a small sample
size. Because of that, even with unrestricted randomization, one group (placebo)
was larger than the other (intervention) group. In addition, it was left at the
discretion of the operator to use resources such as manual thrombus aspiration
device, which was used in 11 patients. Second, we did not measure serum cardiac
enzymes to assess the occurrence of myocardial necrosis. Third, although drug
eluting stents may now be considered the first choice in PPCI, only bare metal
stents were available in our institutions, and we do not think that this would
affect our short-term results. Finally, we did not assess patients' clinical
data after hospital discharge, since their follow-up since then was performed by
their referring physicians.</p></sec></sec></body><back><fn-group><fn fn-type="con"><p><bold>Author contributions</bold></p><p>Conception and design of the research: Lago IM, Figueiredo GL, Lima Filho MO,
Marin Neto JA; Acquisition of data: Lago IM, Novaes GC, Badran AV, Pav&#x000e3;o
RB, Barbosa R, Figueiredo GL, Lima Filho MO, Haddad JL, Marin Neto J&#x000c1;;
Analysis and interpretation of the data: Lago IM, Novaes GC, Figueiredo GL, Lima
Filho MO, Marin Neto J&#x000c1;; Statistical analysis: Lago IM, Lima Filho MO,
Schmidt A, Marin Neto J&#x000c1;; Writing of the manuscript and Critical revision
of the manuscript for intellectual content: Lago IM, Lima Filho MO, Marin Neto
JA; Obtaining financing: Lago IM, Barbosa R, Lima Filho MO, Marin Neto JA.</p></fn><fn fn-type="COI-statement"><p><bold>Potential Conflict of Interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="supported-by"><p><bold>Sources of Funding</bold></p><p>There were no external funding sources for this study.</p></fn><fn fn-type="other"><p><bold>Study Association</bold></p><p>This article is part of the thesis of Doctoral submitted by Igor Matos Lago, from
Hospital das Cl&#x000ed;nicas da Faculdade de Medicina de Ribeir&#x000e3;o Preto -
Universidade de S&#x000e3;o Paulo.</p></fn></fn-group><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd-Jones</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>R</given-names></name><name><surname>Carnethon</surname><given-names>M</given-names></name><name><surname>De Simone</surname><given-names>G</given-names></name><name><surname>Ferguson</surname><given-names>TB</given-names></name><name><surname>Flegal</surname><given-names>K</given-names></name><etal/><collab>American Heart Association Statistics Committee and Stroke
Statistics Subcommittee</collab></person-group><article-title>Heart disease and stroke statistics-2009 update: a report from
the American Heart Association Statistics Committee and Stroke Statistics
Subcommittee</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>3</issue><fpage>480</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">19171871</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widimsky</surname><given-names>P</given-names></name><name><surname>Wijns</surname><given-names>W</given-names></name><name><surname>Fajadet</surname><given-names>J</given-names></name><name><surname>De Belderm</surname></name><name><surname>Knot</surname><given-names>J</given-names></name><name><surname>Aaberge</surname><given-names>L</given-names></name><etal/><collab>European Association for Percutaneous Cardiovascular
Interventions</collab></person-group><article-title>Reperfusion therapy for ST elevation acute myocardial infarction
in Europe: description of the current situation in 30
countries</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><issue>8</issue><fpage>943</fpage><lpage>957</lpage><pub-id pub-id-type="pmid">19933242</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keeley</surname><given-names>EC</given-names></name><name><surname>Boura</surname><given-names>JA</given-names></name><name><surname>Grines</surname><given-names>CI</given-names></name></person-group><article-title>Primary angioplasty versus intravenous thrombolytic therapy for
acute myocardial infarction: a quantitative review of 23 randomised
trials</article-title><source>Lancet</source><year>2003</year><volume>361</volume><issue>9351</issue><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12517460</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezkalla</surname><given-names>SH</given-names></name><name><surname>Kloner</surname><given-names>RA</given-names></name></person-group><article-title>Coronary no-reflow phenomenon: from the experimental laboratory
to the cardiac catheterization laboratory</article-title><source>Cath Cardiovasc Interv</source><year>2008</year><volume>72</volume><issue>7</issue><fpage>950</fpage><lpage>957</lpage></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brosh</surname><given-names>D</given-names></name><name><surname>Assali</surname><given-names>AR</given-names></name><name><surname>Mager</surname><given-names>A</given-names></name><name><surname>Porter</surname><given-names>A</given-names></name><name><surname>Hasdai</surname><given-names>D</given-names></name><name><surname>Teplitsky</surname><given-names>I</given-names></name></person-group><article-title>Effect of no reflow during primary percutaneous coronary
intervention for acute myocardial infarction on six-month
mortality</article-title><source>Am J Cardiol</source><year>2007</year><volume>99</volume><issue>4</issue><fpage>442</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">17293180</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ndrepela</surname><given-names>G</given-names></name><name><surname>Tiroch</surname><given-names>K</given-names></name><name><surname>Keta</surname><given-names>D</given-names></name><name><surname>Fusaro</surname><given-names>M</given-names></name><name><surname>Seyfarth</surname><given-names>M</given-names></name><name><surname>Pache</surname><given-names>J</given-names></name><etal/></person-group><article-title>Predictive factors and impact of no-reflow after primary
percutaneous coronary intervention in patients with acute myocardial
infarction</article-title><source>Circ Cardiovasc Intervent</source><year>2010</year><volume>3</volume><issue>1</issue><fpage>27</fpage><lpage>33</lpage></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoli</surname><given-names>G</given-names></name><name><surname>Burzotta</surname><given-names>F</given-names></name><name><surname>Galiuto</surname><given-names>L</given-names></name><name><surname>Crea</surname><given-names>F</given-names></name></person-group><article-title>Myocardial no-reflow in humans</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>54</volume><issue>4</issue><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">19608025</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pocock</surname><given-names>ST</given-names></name></person-group><source>Clinical trials:a practical approach</source><year>1983</year><publisher-loc>Chichester</publisher-loc><publisher-name>John Wiley and Sons</publisher-name></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>STATACORP</collab></person-group><source>Stata. Release 13 Statistical Software</source><year>2013</year><publisher-loc>College Station TX</publisher-loc><publisher-name>Stata Corp LP</publisher-name></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van't Hof</surname><given-names>AW</given-names></name><name><surname>Liem</surname><given-names>A</given-names></name><name><surname>Surypranata</surname><given-names>H</given-names></name><name><surname>Hoornntje</surname><given-names>JCA</given-names></name><name><surname>Jan De Boer</surname><given-names>M</given-names></name><name><surname>Zijlstra</surname><given-names>F</given-names></name></person-group><article-title>Zwolle Myocardial Infarction Study Group. Angiographic assessment
of myocardial reperfusion in patients treated with primary angioplasty for
acute myocardial infarction: myocardial blush grade</article-title><source>Circulation</source><year>1998</year><volume>97</volume><issue>23</issue><fpage>2302</fpage><lpage>2306</lpage><pub-id pub-id-type="pmid">9639373</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giugliano</surname><given-names>RP</given-names></name><name><surname>Sabatine</surname><given-names>MS</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><name><surname>Roe</surname><given-names>MT</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Murphy</surname><given-names>SA</given-names></name></person-group><article-title>Combined assessment of thrombolysis in myocardial infarction flow
grade, myocardial perfusion grade, and ST-segment resolution to evaluate
epicardial and myocardial reperfusion</article-title><source>Am J Cardiol</source><year>2004</year><volume>93</volume><issue>11</issue><fpage>1362</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">15165915</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Ucci</surname><given-names>G</given-names></name><name><surname>Cassetti</surname><given-names>E</given-names></name><name><surname>Marino</surname><given-names>P</given-names></name></person-group><article-title>Benefits From Small Molecule Administration as Compared With
Abciximab Among Patients With ST-Segment Elevation Myocardial Infarction
Treated With Primary Angioplasty. A Meta-Analysis</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>53</volume><issue>18</issue><fpage>1668</fpage><lpage>1673</lpage><pub-id pub-id-type="pmid">19406342</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skyschally</surname><given-names>A</given-names></name><name><surname>Leineweber</surname><given-names>K</given-names></name><name><surname>Gres</surname><given-names>P</given-names></name><name><surname>Haude</surname><given-names>M</given-names></name><name><surname>Erbel</surname><given-names>R</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name></person-group><article-title>Coronary microembolization</article-title><source>Basic Res Cardiol</source><year>2006</year><volume>101</volume><issue>5</issue><fpage>373</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">16915530</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burzotta</surname><given-names>F</given-names></name><name><surname>Testa</surname><given-names>L</given-names></name><name><surname>Giannico</surname><given-names>F</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>GGL</given-names></name><name><surname>Trani</surname><given-names>C</given-names></name><name><surname>Romagnoli</surname><given-names>E</given-names></name><etal/></person-group><article-title>Adjunctive devices in primary or rescue PCI: a meta-analysis of
randomized trials</article-title><source>Int J Cardiol</source><year>2008</year><volume>123</volume><issue>3</issue><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">17383756</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>MG</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Aymong</surname><given-names>E</given-names></name><name><surname>Gardner</surname><given-names>G</given-names></name><name><surname>Mehran</surname><given-names>R</given-names></name><name><surname>Lansky</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Controlled Abciximab and Device Investigation to Lower Late
Angioplasty Complications trial. Prognostic utility of comparative methods
for assessment of ST-segment resolution after primary angioplasty for acute
myocardial infarction: the Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications (CADILLAC) trial</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>44</volume><issue>6</issue><fpage>1215</fpage><lpage>1223</lpage><pub-id pub-id-type="pmid">15364322</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>ZM</given-names></name><name><surname>Jiang</surname><given-names>LX</given-names></name><name><surname>Chen</surname><given-names>YP</given-names></name><name><surname>Xie</surname><given-names>JX</given-names></name><name><surname>Pan</surname><given-names>HC</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name><etal/><collab>COMMIT Collaborative Group</collab></person-group><article-title>Addition of clopidogrel to aspirin in 45852 patients with acute
myocardial infarction: randomised placebo-controlled trial</article-title><source>Lancet</source><year>2005</year><volume>366</volume><issue>9497</issue><fpage>1607</fpage><lpage>1621</lpage><pub-id pub-id-type="pmid">16271642</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatine</surname><given-names>MS</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><name><surname>L&#x000f3;pez-Sendon</surname><given-names>JL</given-names></name><name><surname>Montalescot</surname><given-names>G</given-names></name><name><surname>Theroux</surname><given-names>P</given-names></name><etal/></person-group><article-title>Clopidogrel as Adjunctive Reperfusion Therapy
(CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators.
Effect of clopidogrel pretreatment before percutaneous coronary intervention
in patients with ST-elevation myocardial infarction treated
with</article-title><source>JAMA</source><year>2005</year><volume>294</volume><issue>10</issue><fpage>1224</fpage><lpage>1232</lpage><pub-id pub-id-type="pmid">16143698</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>RW</given-names></name><name><surname>Aggarwal</surname><given-names>A</given-names></name><name><surname>Fang-Shu</surname><given-names>O</given-names></name><name><surname>Lloyd</surname><given-names>WK</given-names></name><name><surname>Klein</surname><given-names>LW</given-names></name><name><surname>Rumsfeld</surname><given-names>JS</given-names></name></person-group><article-title>Incidence and Outcomes of No-Reflow Phenomenon During
Percutaneous Coronary Intervention Among Patients With Acute Myocardial
Infarction</article-title><source>Am J Cardiol</source><year>2013</year><volume>111</volume><issue>2</issue><fpage>178</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">23111142</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Suryapranata</surname><given-names>H</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Antoniucci</surname><given-names>D</given-names></name><name><surname>Tcheng</surname><given-names>JE</given-names></name><name><surname>Neumann</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Abciximab as adjunctive therapy to reperfusion in acute
ST-segment elevation myocardial infarction: a meta-analysis of randomized
trials</article-title><source>JAMA</source><year>2005</year><volume>293</volume><issue>14</issue><fpage>1759</fpage><lpage>1765</lpage><pub-id pub-id-type="pmid">15827315</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalescot</surname><given-names>G</given-names></name><name><surname>Antoniucci</surname><given-names>D</given-names></name><name><surname>Kastrati</surname><given-names>A</given-names></name><name><surname>Neumann</surname><given-names>FJ</given-names></name><name><surname>Borentain</surname><given-names>M</given-names></name><name><surname>Migliorini</surname><given-names>A</given-names></name><etal/></person-group><article-title>Abciximab in primary coronary stenting of ST-elevation myocardial
infarction: a European meta-analysis on individual patient's data with
long-term follow-up</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><issue>4</issue><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">17251257</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Lemos</surname><given-names>JA</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>ST segment resolution as a tool for assessing the efficacy of
reperfusion therapy</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>38</volume><issue>5</issue><fpage>1283</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">11691496</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroder</surname><given-names>R</given-names></name></person-group><article-title>Prognostic impact of early ST-segment resolution in acute
ST-elevation myocardial infarction</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>21</issue><fpage>e506</fpage><lpage>e510</lpage><pub-id pub-id-type="pmid">15557381</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorajja</surname><given-names>P</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><name><surname>Costantini</surname><given-names>C</given-names></name><name><surname>MacLaughlin</surname><given-names>MG</given-names></name><name><surname>Zimetbaum</surname><given-names>P</given-names></name><name><surname>Cox</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Combined prognostic utility of ST-segment recovery and myocardial
blush after primary percutaneous coronary intervention in acute myocardial
infarction</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><issue>7</issue><fpage>667</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">15734768</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Hamm</surname><given-names>CW</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><name><surname>Mahaffey</surname><given-names>KW</given-names></name><collab>CHAMPION Investigators</collab><etal/></person-group><article-title>Effect of cangrelor on periprocedural outcomes in percutaneous
coronary interventions: a pooled analysis of patient-level
data</article-title><source>Lancet</source><year>2013</year><volume>382</volume><issue>9909</issue><fpage>1981</fpage><lpage>1992</lpage><pub-id pub-id-type="pmid">24011551</pub-id></element-citation></ref></ref-list></back></article>